Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	ATM Common stock	ATM Additional paid-in capital	ATM	PIPE Funding Common stock	PIPE Funding Additional paid-in capital	PIPE Funding	Common stock	Additional paid-in capital	Accumulated Other Comprehensive Income	Accumulated deficit	Total
Balance at Dec. 31, 2021							$ 1	$ 127,289		$ (79,105)	$ 48,185
Balance (shares) at Dec. 31, 2021							12,110,373
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense								5,332			5,332
Exercise of stock options								32			32
Exercise of stock options (shares)							18,470
Net Income (Loss)										(36,896)	(36,896)
Balance at Dec. 31, 2022							$ 1	132,653		(116,001)	16,653
Balance (shares) at Dec. 31, 2022							12,128,843
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Unrealized gain on marketable securities									$ 22		22
Share-based compensation expense								6,153			6,153
Issuance of common stock		$ 34	$ 34	$ 2	$ 116,001	$ 116,003		221			221
Issuance of common stock ( in shares)	5,925			21,690,871			55,250
Vesting of restricted stock awards								70			70
Vesting of restricted stock awards (shares)							12,498
Exercise of stock options								371			$ 371
Exercise of stock options (shares)							522,681				651,240
Issuance of common stock and stock-based equity awards for MorphImmune merger							$ 1	87,160			$ 87,161
Issuance of common stock and stock-based equity awards for MorphImmune merger (shares)							8,835,710
Net Income (Loss)										(106,806)	(106,806)
Balance at Dec. 31, 2023							$ 4	$ 342,663	$ 22	$ (222,807)	$ 119,882
Balance (shares) at Dec. 31, 2023							43,251,778